Pulse Biosciences (PLSE) Cash & Equivalents (2015 - 2026)

Pulse Biosciences' Cash & Equivalents history runs 11 years deep, the most recent figure standing at $80.7 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 31.63% year-over-year to $80.7 million; the TTM figure through Dec 2025 stood at $80.7 million (down 31.63% YoY), while the FY2025 annual figure was $80.7 million, down 31.63% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $80.7 million, down from $95.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $119.3 million in Q1 2025, with the low at $12.7 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $55.2 million (2023), against an average of $60.7 million.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents soared 661.48% in 2021, then sank 78.83% in 2022.
• Pulse Biosciences' Cash & Equivalents stood at $44.4 million in 2021, then surged by 30.67% to $58.0 million in 2022, then fell by 23.47% to $44.4 million in 2023, then soared by 166.06% to $118.0 million in 2024, then tumbled by 31.63% to $80.7 million in 2025.
• Business Quant data shows PLSE's Cash & Equivalents at $80.7 million in Q4 2025, $95.2 million in Q3 2025, and $106.3 million in Q2 2025.